TIL Therapy in cSCC and MCC

TIL Therapy in cSCC and MCC
Conditions: Cutaneous Squamous Cell Carcinoma; Merkel Cell Carcinoma; Metastatic Cutaneous Squamous Cell Carcinoma; Skin Cancer

Interventions: Biological: LN-145; Drug: Cyclophosphamide; Drug: Fludarabine; Biological: Interleukin-2

Sponsors: Karam Khaddour; Iovance Biotherapeutics, Inc.

Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

December 18, 2025Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments